A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination With or Without Ipilimumab

BACKGROUND: Transgenic adoptive cell therapy (ACT) targeting the tumor antigen NY-ESO-1 can be effective for the treatment of sarcoma and melanoma. Preclinical models have shown that this therapy can be improved with the addition of dendritic cell (DC) vaccination and immune checkpoint blockade. We...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Nowicki, Theodore S., Berent-Maoz, Beata, Cheung-Lau, Gardenia, Huang, Rong Rong, Wang, Xiaoyan, Tsoi, Jennifer, Kaplan-Lefko, Paula, Paula Cabrera, Tran, Justin, Pang, Jia, Macabali, Mignonette, Garcilazo, Ivan Perez, Carretero, Ignacio Baselga, Kalbasi, Anusha, Cochran, Alistair J., Grasso, Catherine S., Hu-Lieskovan, Siwen, Chmielowski, Bartosz, Comin-Anduix, Begoña, Singh, Arun, Ribas, Antoni
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6445780/
https://ncbi.nlm.nih.gov/pubmed/30573690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-3496
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados